Emerging next-generation BTK inhibitors such as orelabrutinib and zanubrutinib are attracting interest as targeted options for adult ITP because of their high BTK selectivity, favourable pharmacokinetics, and mechanistic potential to suppress pathogenic B-cell activity and FcγR-mediated macrophage platelet clearance. Here, BTK is linked to autoimmune thrombocytopenic purpura.